Antigen

Newark, New Castle, USA, June 13, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global carcinoembryonic antigen market was conducted by Growth Plus Reports in 2022 and was valued at US$ 2.66 billion. The market is expected to hit a…

Newark, New Castle, USA, June 06, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global rapid antigen testing market was conducted by Growth Plus Reports in 2022. The market is expected to hit a revenue CAGR of 13.01% by 2031.…

If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as -DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging.Proven track record of -DCFPyL…

<!-- Name:DistributionId Value:8807924 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:5377 -->…

New York, Nov. 30, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "Immunodiagnostics Market Size, Share, Growth, Trends and Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Clinical…

Myocarditis is a complication that can occur in cancer patients treated with immune checkpoint inhibitors. Although the adverse event is rare -- affecting less than 1% of patients given the immunotherapy -- the mortality rate is nearly 50%.…

JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the…

About 60% of healthcare workers participating in an optional rapid antigen testing program at UCLA tested positive at day five, and about 50% were positive at day seven after initially testing positive for COVID-19 with a PCR test. The…

From the makers of INSTI®, bioLytical launches a new platform, iStatis, created to ensure every person in the world has access to reliable testingbioLytical receives eligibility for its self-test, the iStatis COVID-19 Antigen Home Test,…

A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in…